वैकल्पिक उत्पाद विश्लेषण
आपकी अनुमति से हम गोपनीयता-सीमित विश्लेषण का उपयोग करके समझते हैं कि कौन-सी शोध यात्राएँ उपयोगी हैं। हम विज्ञापन ट्रैकर या सत्र रिकॉर्डिंग नहीं चलाते। आप यह विकल्प प्राथमिकताओं में बदल सकते हैं। पढ़ें गोपनीयता नीति.
Gilead Sciences Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $187.2B | |
|---|---|---|
| P/E (forward) | 15.4x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $27.31B | $27.28B | $27.12B | $28.75B | $29.44B | +1.9% |
| Gross profit | $20.70B | $21.62B | $27.12B | $22.50B | $23.21B | +2.9% |
| Operating income | $9.92B | $7.33B | $7.61B | $1.66B | $10.02B | +0.3% |
| Net income | $6.23B | $4.59B | $5.67B | $480.0M | $8.51B | +8.1% |
| EPS (diluted) | $4.93 | $3.64 | $4.50 | $0.38 | $6.78 | +8.3% |
| EBITDA | $11.33B | $8.85B | $7.61B | $4.43B | $13.58B | +4.6% |
| R&D | $4.60B | $4.98B | $5.72B | $5.91B | $5.80B | +6.0% |
| SG&A | $5.25B | $5.67B | $6.09B | $6.09B | $5.77B | +2.4% |
Recent company headlines from major financial publishers.
FY2027 analyst consensus estimates support higher revenue and adjusted earnings. Growth then slows because HIV concentration limits the evidence for a longer expansion.
Improvement beyond FY2027 requires a larger non-HIV contribution and strong free cash flow. These are scenario conditions, while the cited evidence records FY2025 levels. Lower cell-therapy sales or weaker free cash flow would disconfirm this path.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 4.9% | $166 | $180 | $199 | $228 | $276 |
| 5.9% | $143 | $151 | $160 | $174 | $192 |
| 6.9% | $128 | $133 | $140 | $146 | $155 |
| 7.9% | $117 | $120 | $124 | $129 | $134 |
| 8.9% | $109 | $111 | $114 | $117 | $121 |
Upcoming earnings date and setup when available.
हर महीने प्रकाशित शोध संस्करण की रेटिंग। रेटिंग विश्लेषण की तारीख की कीमत की तुलना उचित मूल्य से करती है; यह इस बात का रिकॉर्ड नहीं है कि आकलन सही निकला या नहीं।
| वर्ष | जन॰ | फ़र॰ | मार्च | अप्रैल | मई | जून | जुल॰ | अग॰ | सित॰ | अक्टू॰ | नव॰ | दिस॰ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
